Kontour (Xi'an) Medical Technology Co., Ltd. (SHA:688314)
China · Delayed Price · Currency is CNY 38.94
-0.17 (-0.43%)
Feb 13, 2026, 3:00 PM CST
SHA:688314 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 322.68 | 311.71 | 262.63 | 229.61 | 206.31 | 158.34 |
Other Revenue | 10.23 | 10.23 | 12.4 | 10.34 | 6.24 | 5.73 |
| 332.92 | 321.95 | 275.03 | 239.95 | 212.55 | 164.08 | |
Revenue Growth (YoY) | 7.90% | 17.06% | 14.62% | 12.89% | 29.54% | 11.01% |
Cost of Revenue | 74.21 | 67.93 | 60.38 | 50.19 | 41.99 | 32.16 |
Gross Profit | 258.71 | 254.01 | 214.65 | 189.76 | 170.56 | 131.92 |
Selling, General & Admin | 117.54 | 119.76 | 107.33 | 91.58 | 75.18 | 64.55 |
Research & Development | 25.48 | 23.9 | 17.64 | 18.3 | 16.8 | 16.9 |
Other Operating Expenses | 14.01 | 4.64 | 4.42 | 4.03 | 2.77 | 1.57 |
Operating Expenses | 157.08 | 147.96 | 129.38 | 114.11 | 94.71 | 82.96 |
Operating Income | 101.63 | 106.05 | 85.26 | 75.64 | 75.85 | 48.95 |
Interest Expense | -2.17 | -2.17 | -1.89 | -1.23 | -0.74 | -0.37 |
Interest & Investment Income | 2.11 | 5.22 | 5.2 | 8.14 | 4.85 | 3.12 |
Currency Exchange Gain (Loss) | -0.37 | -0.37 | 0.23 | 0.49 | 0.03 | -0.56 |
Other Non Operating Income (Expenses) | -1.44 | -1.75 | -0.3 | -0.2 | -0.17 | -0.18 |
EBT Excluding Unusual Items | 99.75 | 106.98 | 88.5 | 82.85 | 79.82 | 50.97 |
Gain (Loss) on Sale of Investments | -14.18 | -12.59 | -1.86 | - | - | - |
Gain (Loss) on Sale of Assets | 0.03 | 0.44 | -0.06 | -0 | 0.02 | -0.02 |
Asset Writedown | -0.02 | -1.87 | - | -0.04 | -0.35 | -0.01 |
Other Unusual Items | 17.82 | 13.04 | 5.18 | 5.66 | 15.9 | 7.28 |
Pretax Income | 103.4 | 106 | 91.75 | 88.46 | 95.39 | 58.21 |
Income Tax Expense | 15.86 | 18.37 | 17.28 | 14.3 | 14.21 | 7.1 |
Earnings From Continuing Operations | 87.54 | 87.64 | 74.47 | 74.16 | 81.18 | 51.12 |
Minority Interest in Earnings | 0.87 | 0.76 | 1.04 | 1.53 | 0.44 | 1.26 |
Net Income | 88.4 | 88.4 | 75.51 | 75.69 | 81.63 | 52.38 |
Net Income to Common | 88.4 | 88.4 | 75.51 | 75.69 | 81.63 | 52.38 |
Net Income Growth | 0.60% | 17.07% | -0.23% | -7.28% | 55.83% | 0.86% |
Shares Outstanding (Basic) | 81 | 81 | 81 | 81 | 73 | 61 |
Shares Outstanding (Diluted) | 81 | 81 | 81 | 81 | 73 | 61 |
Shares Change (YoY) | -0.26% | -0.12% | -0.23% | 11.81% | 19.10% | 2.55% |
EPS (Basic) | 1.09 | 1.09 | 0.93 | 0.93 | 1.12 | 0.86 |
EPS (Diluted) | 1.09 | 1.09 | 0.93 | 0.93 | 1.12 | 0.86 |
EPS Growth | 0.86% | 17.20% | - | -17.07% | 30.84% | -1.64% |
Free Cash Flow | 68.04 | 92.86 | 71 | 73.78 | 48.05 | -15.15 |
Free Cash Flow Per Share | 0.84 | 1.15 | 0.87 | 0.91 | 0.66 | -0.25 |
Dividend Per Share | 0.380 | 0.360 | 0.320 | 0.371 | 0.443 | 0.371 |
Dividend Growth | -24.00% | 12.50% | -13.84% | -16.14% | 19.25% | - |
Gross Margin | 77.71% | 78.90% | 78.05% | 79.08% | 80.25% | 80.40% |
Operating Margin | 30.53% | 32.94% | 31.00% | 31.52% | 35.69% | 29.84% |
Profit Margin | 26.55% | 27.46% | 27.46% | 31.54% | 38.40% | 31.92% |
Free Cash Flow Margin | 20.44% | 28.84% | 25.82% | 30.75% | 22.61% | -9.23% |
EBITDA | 113.53 | 117.29 | 95.62 | 85.56 | 83.02 | 55.28 |
EBITDA Margin | 34.10% | 36.43% | 34.77% | 35.66% | 39.06% | 33.69% |
D&A For EBITDA | 11.89 | 11.24 | 10.36 | 9.91 | 7.17 | 6.32 |
EBIT | 101.63 | 106.05 | 85.26 | 75.64 | 75.85 | 48.95 |
EBIT Margin | 30.53% | 32.94% | 31.00% | 31.52% | 35.69% | 29.84% |
Effective Tax Rate | 15.34% | 17.33% | 18.83% | 16.17% | 14.90% | 12.19% |
Revenue as Reported | 332.92 | 321.95 | 275.03 | 239.95 | 212.55 | 164.08 |
Advertising Expenses | - | 16.02 | 17.77 | 19.97 | 17.68 | 15.71 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.